Heart Test Laboratories, Inc. d/b/a HeartSciences, an artificial intelligence (AI)-based medical technology company focused on transforming ECGs/EKGs to save lives through earlier detection of heart disease, announced that its MyoVista® wavECGTM has been selected by PanaceaFlo Ltd. to be used in Dublin, Ireland in its heart screening evaluation study. The main objective of the study is to establish a cardiovascular risk screening program and integrated care hub pathway. If successful, the program is expected to roll out nationally in Ireland, in conjunction with the Irish Health Elevator Program, focusing on community-based screening and early intervention of cardiovascular risk in line with the Irish public health system (HSE) ?Stayleft, Shiftleft10X?

transformation program to move to preventative rather than acute care. It will initially screen approximately 250 members of the general public, including Garda Siochana officers, in Dublin, Ireland, in collaboration with the Innovation Value Institute (IVI), Maynooth University College, Kildare.